6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Cytopenias	NNP	cytopenias	cytopenia	cytopenia	N	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
Fibrillation	NNP	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Second	JJ	second	second	second	N	B-AdverseReaction
Primary	NNP	primary	primary	primari	N	I-AdverseReaction
Malignancies	NNPS	malignancies	malignancy	malign	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
Lysis	NNP	lysis	lysis	lysi	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
variable	JJ	variable	variable	variabl	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O

:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
B	NNP	b	b	b	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
(	(	(	(	(	N	O
MCL	NNP	mcl	mcl	mcl	N	O
,	,	,	,	,	N	O
CLL	NNP	cll	cll	cll	Y	O
,	,	,	,	,	N	O
WM	NNP	wm	wm	wm	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
thrombocytopenia	JJ	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
bruising	NN	bruising	bruising	bruis	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Pharmacyclics	NNS	pharmacyclics	pharmacyclics	pharmacycl	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
3536	CD	3536	3536	3536	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Mantle	NNP	mantle	mantle	mantl	N	O
Cell	NNP	cell	cell	cell	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
included	VBD	included	included	includ	N	O
111	CD	111	111	111	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
previously	RB	previously	previously	previous	N	O
treated	VBN	treated	treated	treat	N	O
MCL	NNP	mcl	mcl	mcl	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
560	CD	560	560	560	N	O
mg	NNS	mg	mg	mg	N	O
daily	RB	daily	daily	daili	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
treatment	NN	treatment	treatment	treatment	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
8.3	CD	8.3	8.3	8.3	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	JJ	commonly	commonly	commonli	N	O
occurring	VBG	occurring	occurring	occur	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
thrombocytopenia	JJ	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
bruising	NN	bruising	bruising	bruis	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
and	CC	and	and	and	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Tables	NNP	tables	table	tabl	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
hematological	JJ	hematological	hematological	hematolog	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
pneumonia	VBN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
1.5	CD	1.5	1.5	1.5	N	B-Severity
to	TO	to	to	to	N	I-Severity
3	CD	3	3	3	N	I-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
9%	CD	9%	9%	9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
MCL	NNP	mcl	mcl	mcl	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
111	CD	111	111	111	N	O
)	)	)	)	)	N	O
using	VBG	using	using	use	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
560	CD	560	560	560	N	O
mg	JJ	mg	mg	mg	N	O
daily	JJ	daily	daily	daili	N	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
Hematologic	NNP	hematologic	hematologic	hematolog	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MCL	NNP	mcl	mcl	mcl	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
111	CD	111	111	111	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

disorders	NNS	disorders	disorder	disord	N	O
Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
51	CD	51	51	51	N	O
5	CD	5	5	5	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
31	CD	31	31	31	N	O
0	CD	0	0	0	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
25	CD	25	25	25	N	O
0	CD	0	0	0	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
24	CD	24	24	24	N	O
5	CD	5	5	5	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
23	CD	23	23	23	N	O
0	CD	0	0	0	N	O

Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
17	CD	17	17	17	N	O
1	CD	1	1	1	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
34	CD	34	34	34	N	O
0	CD	0	0	0	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
14	CD	14	14	14	N	O
3	CD	3	3	3	N	O

Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
7	CD	7	7	7	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
14	CD	14	14	14	N	O
5	CD	5	5	5	N	O

Sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administrative	JJ	administrative	administrative	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
Fatigue	VBP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
41	CD	41	41	41	N	O
5	CD	5	5	5	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	VBD	edema	edema	edema	Y	I-AdverseReaction
35	CD	35	35	35	N	O
3	CD	3	3	3	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
18	CD	18	18	18	N	O
1	CD	1	1	1	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
3	CD	3	3	3	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Bruising	VBG	bruising	bruising	bruis	Y	B-AdverseReaction
30	CD	30	30	30	N	O
0	CD	0	0	0	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
25	CD	25	25	25	N	O
3	CD	3	3	3	N	O

Petechiae	NNP	petechiae	petechia	petechia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	VBD	pain	pain	pain	Y	I-AdverseReaction
37	CD	37	37	37	N	O
1	CD	1	1	1	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	VBD	spasms	spasm	spasm	Y	I-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
Dyspnea	VBP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
27	CD	27	27	27	N	O
4	CD	4	4	4	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O

Epistaxis	NNP	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
Decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
21	CD	21	21	21	N	O
2	CD	2	2	2	N	O

Dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
12	CD	12	12	12	N	O
4	CD	4	4	4	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
EmergentBased	VBN	emergentbased	emergentbased	emergentbas	N	O
on	IN	on	on	on	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
measurements	NNS	measurements	measurement	measur	N	O
and	CC	and	and	and	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
Decrease	NNP	decrease	decrease	decreas	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
Platelets	NNP	platelets	platelet	platelet	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
Neutrophils	NNP	neutrophils	neutrophil	neutrophil	Y	I-AdverseReaction
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MCL	NNP	mcl	mcl	mcl	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
111	CD	111	111	111	N	O
)	)	)	)	)	N	O

Percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
Patients	NNP	patients	patient	patient	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
111	CD	111	111	111	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction

Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
57	CD	57	57	57	N	O
17	CD	17	17	17	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
47	CD	47	47	47	N	O
29	CD	29	29	29	N	O

Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
41	CD	41	41	41	N	O
9	CD	9	9	9	N	O

Ten	CD	ten	ten	ten	Y	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
111	CD	111	111	111	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
was	VBD	was	wa	wa	N	O
subdural	JJ	subdural	subdural	subdur	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O

with	IN	with	with	with	N	O
MCL	NNP	mcl	mcl	mcl	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
lymphocytosis	NN	lymphocytosis	lymphocytosis	lymphocytosi	Y	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
400	CD	400	400	400	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
mcL	NNS	mcl	mcl	mcl	N	O
have	VBP	have	have	have	N	O
developed	VBN	developed	developed	develop	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O
,	,	,	,	,	N	O
lethargy	NN	lethargy	lethargy	lethargi	Y	O
,	,	,	,	,	N	O
gait	NN	gait	gait	gait	N	O
instability	NN	instability	instability	instabl	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
were	VBD	were	were	were	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
of	IN	of	of	of	N	O
disease	NN	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
.	.	.	.	.	N	O

Forty	NNP	forty	forty	forti	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
uric	JJ	uric	uric	uric	N	I-AdverseReaction
acid	NN	acid	acid	acid	N	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
on	IN	on	on	on	N	O
study	NN	study	study	studi	N	O
including	VBG	including	including	includ	N	O
13%	CD	13%	13%	13%	N	O
with	IN	with	with	with	N	O
values	NNS	values	value	valu	N	O
above	IN	above	above	abov	N	B-Severity
10	CD	10	10	10	N	I-Severity
mg	NN	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
hyperuricemia	NN	hyperuricemia	hyperuricemia	hyperuricemia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Chronic	NNP	chronic	chronic	chronic	N	O
Lymphocytic	NNP	lymphocytic	lymphocytic	lymphocyt	N	O
Leukemia	NNP	leukemia	leukemia	leukemia	Y	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
open	JJ	open	open	open	N	O
label	NN	label	label	label	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
included	VBD	included	included	includ	N	O
48	CD	48	48	48	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
previously	RB	previously	previously	previous	N	O
treated	VBN	treated	treated	treat	N	O
CLL	NNP	cll	cll	cll	Y	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
included	VBD	included	included	includ	N	O
391	CD	391	391	391	N	O
randomized	JJ	randomized	randomized	random	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
previously	RB	previously	previously	previous	N	O
treated	VBN	treated	treated	treat	N	O
CLL	NNP	cll	cll	cll	Y	O
or	CC	or	or	or	N	O
SLL	NNP	sll	sll	sll	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	JJ	commonly	commonly	commonli	N	O
occurring	VBG	occurring	occurring	occur	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
thrombocytopenia	JJ	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
five	CD	five	five	five	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
included	VBD	included	included	includ	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
subdural	JJ	subdural	subdural	subdur	N	B-AdverseReaction
hematomas	NN	hematomas	hematoma	hematoma	N	I-AdverseReaction
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
CLL	NNP	cll	cll	cll	Y	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
48	CD	48	48	48	N	O
)	)	)	)	)	N	O
using	VBG	using	using	use	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
420	CD	420	420	420	N	O
mg	JJ	mg	mg	mg	N	O
daily	JJ	daily	daily	daili	N	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Tables	NNP	tables	table	tabl	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
Hematologic	NNP	hematologic	hematologic	hematolog	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CLL	NNP	cll	cll	cll	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
48	CD	48	48	48	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

disorders	NNS	disorders	disorder	disord	N	O
Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
63	CD	63	63	63	N	O
4	CD	4	4	4	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
23	CD	23	23	23	N	O
2	CD	2	2	2	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
21	CD	21	21	21	N	O
2	CD	2	2	2	N	O

Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
19	CD	19	19	19	N	O
2	CD	2	2	2	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
48	CD	48	48	48	N	O
2	CD	2	2	2	N	O

Sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
21	CD	21	21	21	N	O
6	CD	6	6	6	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
17	CD	17	17	17	N	O
6	CD	6	6	6	N	O

Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
10	CD	10	10	10	N	O
8	CD	8	8	8	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administrative	JJ	administrative	administrative	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
Fatigue	VBP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
31	CD	31	31	31	N	O
4	CD	4	4	4	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
25	CD	25	25	25	N	O
2	CD	2	2	2	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	VBD	edema	edema	edema	Y	I-AdverseReaction
23	CD	23	23	23	N	O
0	CD	0	0	0	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
4	CD	4	4	4	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Bruising	VBG	bruising	bruising	bruis	Y	B-AdverseReaction
54	CD	54	54	54	N	O
2	CD	2	2	2	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
27	CD	27	27	27	N	O
0	CD	0	0	0	N	O

Petechiae	NNP	petechiae	petechia	petechia	Y	B-AdverseReaction
17	CD	17	17	17	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	VBD	pain	pain	pain	Y	I-AdverseReaction
27	CD	27	27	27	N	O
6	CD	6	6	6	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
23	CD	23	23	23	N	O
0	CD	0	0	0	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	VBD	spasms	spasm	spasm	Y	I-AdverseReaction
19	CD	19	19	19	N	O
2	CD	2	2	2	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
19	CD	19	19	19	N	O
2	CD	2	2	2	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	VBD	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
Decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
17	CD	17	17	17	N	O
2	CD	2	2	2	N	O

Neoplasms	NNP	neoplasms	neoplasm	neoplasm	N	O
benign	NN	benign	benign	benign	N	O
,	,	,	,	,	N	O
malignant	JJ	malignant	malignant	malign	N	O
,	,	,	,	,	N	O
unspecified	JJ	unspecified	unspecified	unspecifi	N	O
Second	NNP	second	second	second	N	B-AdverseReaction
malignancies	NNS	malignancies	malignancy	malign	N	I-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
poisoning	NN	poisoning	poisoning	poison	Y	O
and	CC	and	and	and	N	O
procedural	JJ	procedural	procedural	procedur	N	O
complications	NNS	complications	complication	complic	N	O
Laceration	NNP	laceration	laceration	lacer	Y	B-AdverseReaction
10	CD	10	10	10	N	O
2	CD	2	2	2	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
Anxiety	VBP	anxiety	anxiety	anxieti	Y	B-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
Hypertension	VBP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
17	CD	17	17	17	N	O
8	CD	8	8	8	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
EmergentBased	VBN	emergentbased	emergentbased	emergentbas	N	O
on	IN	on	on	on	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
measurements	NNS	measurements	measurement	measur	N	O
per	IN	per	per	per	N	O
IWCLL	NNP	iwcll	iwcll	iwcll	N	O
criteria	NNS	criteria	criterion	criteria	N	O
and	CC	and	and	and	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
Decrease	NNP	decrease	decrease	decreas	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
Platelets	NNP	platelets	platelet	platelet	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
Neutrophils	NNP	neutrophils	neutrophil	neutrophil	Y	I-AdverseReaction
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CLL	NNP	cll	cll	cll	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
48	CD	48	48	48	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

Percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
Patients	NNP	patients	patient	patient	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
48	CD	48	48	48	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction

Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
71	CD	71	71	71	N	O
10	CD	10	10	10	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
54	CD	54	54	54	N	O
27	CD	27	27	27	N	O

Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
44	CD	44	44	44	N	O
0	CD	0	0	0	N	O

Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O

Adverse	NN	adverse	adverse	advers	N	O

reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
in	IN	in	in	in	N	O
Tables	NNP	tables	table	tabl	N	O
5	CD	5	5	5	N	O
and	CC	and	and	and	N	O
6	CD	6	6	6	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
8.6	CD	8.6	8.6	8.6	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
ofatumumab	VB	ofatumumab	ofatumumab	ofatumumab	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	NN	median	median	median	N	O
of	IN	of	of	of	N	O
5.3	CD	5.3	5.3	5.3	N	O
months	NNS	months	month	month	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
:	:	:	:	:	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
Hematologic	NNP	hematologic	hematologic	hematolog	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
10%	CD	10%	10%	10%	N	O
Reported	NNP	reported	reported	report	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O

IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
195	CD	195	195	195	N	O
)	)	)	)	)	N	O
Ofatumumab	NNP	ofatumumab	ofatumumab	ofatumumab	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
191	CD	191	191	191	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
ADR	NNP	adr	adr	adr	N	O
Term	NNP	term	term	term	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Subjects	NNS	subjects	subject	subject	N	O

with	IN	with	with	with	N	O
multiple	JJ	multiple	multiple	multipl	N	O
events	NNS	events	event	event	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
given	VBN	given	given	given	N	O
ADR	NNP	adr	adr	adr	N	O
term	NN	term	term	term	N	O
are	VBP	are	are	are	N	O
counted	VBN	counted	counted	count	N	O
once	RB	once	once	onc	N	O
only	RB	only	only	onli	N	O
for	IN	for	for	for	N	O
each	DT	each	each	each	N	O
ADR	NNP	adr	adr	adr	N	O
term	NN	term	term	term	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
and	CC	and	and	and	N	O
individual	JJ	individual	individual	individu	N	O
ADR	NNP	adr	adr	adr	N	O
terms	NNS	terms	term	term	N	O
are	VBP	are	are	are	N	O
sorted	VBN	sorted	sorted	sort	N	O
in	IN	in	in	in	N	O
descending	VBG	descending	descending	descend	N	O
frequency	NN	frequency	frequency	frequenc	N	O
order	NN	order	order	order	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
48	CD	48	48	48	N	O
4	CD	4	4	4	N	O
18	CD	18	18	18	N	O
2	CD	2	2	2	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
26	CD	26	26	26	N	O
2	CD	2	2	2	N	O
18	CD	18	18	18	N	O
0	CD	0	0	0	N	O

Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
17	CD	17	17	17	N	O
1	CD	1	1	1	N	O
6	CD	6	6	6	N	O
1	CD	1	1	1	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
1	CD	1	1	1	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
28	CD	28	28	28	N	O
2	CD	2	2	2	N	O
30	CD	30	30	30	N	O
2	CD	2	2	2	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
24	CD	24	24	24	N	O
2	CD	2	2	2	N	O
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
16	CD	16	16	16	N	O
1	CD	1	1	1	N	O
11	CD	11	11	11	N	O
2	CD	2	2	2	N	O

Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
15	CD	15	15	15	N	O
10	CD	10	10	10	N	O
13	CD	13	13	13	N	O
9	CD	9	9	9	N	O

Sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
10	CD	10	10	10	N	O
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
1	CD	1	1	1	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
24	CD	24	24	24	N	O
3	CD	3	3	3	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Petechiae	NNP	petechiae	petechia	petechia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Bruising	VBG	bruising	bruising	bruis	Y	B-AdverseReaction
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
28	CD	28	28	28	N	O
2	CD	2	2	2	N	O
18	CD	18	18	18	N	O
1	CD	1	1	1	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
17	CD	17	17	17	N	O
1	CD	1	1	1	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
poisoning	NN	poisoning	poisoning	poison	Y	O
and	CC	and	and	and	N	O
procedural	JJ	procedural	procedural	procedur	N	O
complications	NNS	complications	complication	complic	N	O

Contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Eye	NN	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O

Vision	NN	vision	vision	vision	N	B-AdverseReaction
blurred	VBD	blurred	blurred	blur	N	I-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
:	:	:	:	:	N	O
Treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
EmergentBased	VBN	emergentbased	emergentbased	emergentbas	N	O
on	IN	on	on	on	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
measurements	NNS	measurements	measurement	measur	N	O
per	IN	per	per	per	N	O
IWCLL	NNP	iwcll	iwcll	iwcll	N	O
criteria	NNS	criteria	criterion	criteria	N	O
Decrease	NNP	decrease	decrease	decreas	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
Platelets	NNP	platelets	platelet	platelet	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
Neutrophils	NNP	neutrophils	neutrophil	neutrophil	Y	I-AdverseReaction
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O

IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
195	CD	195	195	195	N	O
)	)	)	)	)	N	O
Ofatumumab	NNP	ofatumumab	ofatumumab	ofatumumab	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
191	CD	191	191	191	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction

Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
51	CD	51	51	51	N	O
23	CD	23	23	23	N	O
57	CD	57	57	57	N	O
26	CD	26	26	26	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
52	CD	52	52	52	N	O
5	CD	5	5	5	N	O
45	CD	45	45	45	N	O
10	CD	10	10	10	N	O

Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
36	CD	36	36	36	N	O
0	CD	0	0	0	N	O
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Waldenstrom	NNP	waldenstrom	waldenstrom	waldenstrom	N	O
's	POS	's	's	's	N	O
Macroglobulinemia	NNP	macroglobulinemia	macroglobulinemia	macroglobulinemia	Y	O

The	DT	the	the	the	N	O

data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
open	JJ	open	open	open	N	O
label	NN	label	label	label	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
included	VBD	included	included	includ	N	O
63	CD	63	63	63	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
previously	RB	previously	previously	previous	N	O
treated	VBN	treated	treated	treat	N	O
WM	NNP	wm	wm	wm	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	JJ	commonly	commonly	commonli	N	O
occurring	VBG	occurring	occurring	occur	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
WM	NNP	wm	wm	wm	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasms	NNS	spasms	spasm	spasm	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
.	.	.	.	.	N	O

Six	CD	six	six	six	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
WM	NNP	wm	wm	wm	N	O
trial	NN	trial	trial	trial	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
11%	CD	11%	11%	11%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
in	IN	in	in	in	N	O
Tables	NNP	tables	table	tabl	N	O
7	CD	7	7	7	N	O
and	CC	and	and	and	N	O
8	CD	8	8	8	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
11.7	CD	11.7	11.7	11.7	N	O
months	NNS	months	month	month	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
WM	NNP	wm	wm	wm	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
:	:	:	:	:	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
Hematologic	NNP	hematologic	hematologic	hematolog	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Waldenstrom	NNP	waldenstrom	waldenstrom	waldenstrom	N	O
's	POS	's	's	's	N	O
Macroglobulinemia	NNP	macroglobulinemia	macroglobulinemia	macroglobulinemia	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
63	CD	63	63	63	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

The	DT	the	the	the	N	O

system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
and	CC	and	and	and	N	O
individual	JJ	individual	individual	individu	N	O
ADR	NNP	adr	adr	adr	N	O
terms	NNS	terms	term	term	N	O
are	VBP	are	are	are	N	O
sorted	VBN	sorted	sorted	sort	N	O
in	IN	in	in	in	N	O
descending	VBG	descending	descending	descend	N	O
frequency	NN	frequency	frequency	frequenc	N	O
order	NN	order	order	order	N	O
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

disorders	NNS	disorders	disorder	disord	N	O
Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
37	CD	37	37	37	N	O
0	CD	0	0	0	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
16	CD	16	16	16	N	O
0	CD	0	0	0	N	O

Gastroesophageal	NNP	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	VBZ	reflux	reflux	reflux	N	I-AdverseReaction
disease	VB	disease	disease	diseas	N	I-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Rash	VBP	rash	rash	rash	Y	B-AdverseReaction
22	CD	22	22	22	N	O
0	CD	0	0	0	N	O

Bruising	VBG	bruising	bruising	bruis	Y	B-AdverseReaction
16	CD	16	16	16	N	O
0	CD	0	0	0	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administrative	JJ	administrative	administrative	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
Fatigue	VBP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	VBD	spasms	spasm	spasm	Y	I-AdverseReaction
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Arthropathy	NNP	arthropathy	arthropathy	arthropathi	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O

Sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O

Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
6	CD	6	6	6	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
14	CD	14	14	14	N	O
2	CD	2	2	2	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
Epistaxis	VBP	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Neoplasms	NNP	neoplasms	neoplasm	neoplasm	N	O
benign	NN	benign	benign	benign	N	O
,	,	,	,	,	N	O
malignant	JJ	malignant	malignant	malign	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
unspecified	JJ	unspecified	unspecified	unspecifi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
cysts	NNS	cysts	cyst	cyst	N	O
and	CC	and	and	and	N	O
polyps	NNS	polyps	polyp	polyp	Y	O
)	)	)	)	)	N	O
Skin	NNP	skin	skin	skin	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
:	:	:	:	:	N	O
Treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
EmergentBased	VBN	emergentbased	emergentbased	emergentbas	N	O
on	IN	on	on	on	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
measurements	NNS	measurements	measurement	measur	N	O
.	.	.	.	.	N	O

Decrease	NNP	decrease	decrease	decreas	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
Platelets	NNP	platelets	platelet	platelet	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
Neutrophils	NNP	neutrophils	neutrophil	neutrophil	Y	I-AdverseReaction
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
WM	NNP	wm	wm	wm	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
63	CD	63	63	63	N	O
)	)	)	)	)	N	O

Percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
Patients	NNP	patients	patient	patient	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
63	CD	63	63	63	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBZ	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction

Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
43	CD	43	43	43	N	O
13	CD	13	13	13	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
44	CD	44	44	44	N	O
19	CD	19	19	19	N	O

Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
13	CD	13	13	13	N	O
8	CD	8	8	8	N	O

6	CD	6	6	6	N	O
.	.	.	.	.	N	O

2	CD	2	2	2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
(	(	(	(	(	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
angioedema	NNS	angioedema	angioedema	angioedema	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
fever	NN	fever	fever	fever	Y	O
and	CC	and	and	and	N	O
infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
promptly	RB	promptly	promptly	promptli	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Cytopenias	NNS	cytopenias	cytopenia	cytopenia	N	B-AdverseReaction
:	:	:	:	:	N	O
Check	NNP	check	check	check	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
monthly	JJ	monthly	monthly	monthli	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
Fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Second	JJ	second	second	second	N	B-AdverseReaction
Primary	NNP	primary	primary	primari	N	I-AdverseReaction
Malignancies	NNS	malignancies	malignancy	malign	N	I-AdverseReaction
:	:	:	:	:	N	O
Other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
skin	NN	skin	skin	skin	N	B-AdverseReaction
cancers	NNS	cancers	cancer	cancer	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
carcinomas	NN	carcinomas	carcinoma	carcinoma	N	B-AdverseReaction
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
Lysis	NNP	lysis	lysis	lysi	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
TLS	NNP	tls	tl	tl	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
TLS	NNP	tls	tl	tl	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

high	JJ	high	high	high	N	O
tumor	NN	tumor	tumor	tumor	N	O
burden	NN	burden	burden	burden	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Embryo	NNP	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O

Fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction

bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
higher	JJR	higher	higher	higher	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
subdural	JJ	subdural	subdural	subdur	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
,	,	,	,	,	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
and	CC	and	and	and	N	O
post	NN	post	post	post	N	B-AdverseReaction
procedural	JJ	procedural	procedural	procedur	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
bruising	NN	bruising	bruising	bruis	Y	B-AdverseReaction
and	CC	and	and	and	N	O
petechiae	NN	petechiae	petechia	petechia	Y	B-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
half	NN	half	half	half	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
events	NNS	events	event	event	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
well	RB	well	well	well	N	O
understood	RB	understood	understood	understood	N	O
.	.	.	.	.	N	O

IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
may	MD	may	may	may	N	B-Factor
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
antiplatelet	NN	antiplatelet	antiplatelet	antiplatelet	N	O
or	CC	or	or	or	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
therapies	NNS	therapies	therapy	therapi	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
benefit	NN	benefit	benefit	benefit	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
withholding	VBG	withholding	withholding	withhold	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
pre	NN	pre	pre	pre	N	O
and	CC	and	and	and	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
depending	VBG	depending	depending	depend	N	O
upon	IN	upon	upon	upon	N	O
the	DT	the	the	the	N	O
type	NN	type	type	type	N	O
of	IN	of	of	of	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	O
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Infections	NNS	infections	infection	infect	N	O

Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
non	SYM	non	non	non	N	B-Severity
-	:	-	-	-	N	I-Severity
fatal	JJ	fatal	fatal	fatal	N	I-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
to	TO	to	to	to	N	O
26%	CD	26%	26%	26%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
progressive	JJ	progressive	progressive	progress	N	B-AdverseReaction
multifocal	JJ	multifocal	multifocal	multifoc	N	I-AdverseReaction
leukoencephalopathy	NN	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
fever	NN	fever	fever	fever	Y	O
and	CC	and	and	and	N	O
infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
promptly	RB	promptly	promptly	promptli	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Cytopenias	NNP	cytopenias	cytopenia	cytopenia	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
Grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
cytopenias	NNS	cytopenias	cytopenia	cytopenia	N	B-AdverseReaction
including	VBG	including	including	includ	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
19	CD	19	19	19	N	O
to	TO	to	to	to	N	O
29%	CD	29%	29%	29%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
to	TO	to	to	to	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
0	CD	0	0	0	N	O
to	TO	to	to	to	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
monthly	JJ	monthly	monthly	monthli	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Atrial	JJ	atrial	atrial	atrial	N	O
Fibrillation	NN	fibrillation	fibrillation	fibril	Y	O

Atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
and	CC	and	and	and	N	O
atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
flutter	NN	flutter	flutter	flutter	N	I-AdverseReaction
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
6	CD	6	6	6	N	O
to	TO	to	to	to	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	O
infections	NNS	infections	infection	infect	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
previous	JJ	previous	previous	previou	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
.	.	.	.	.	N	O

Periodically	RB	periodically	periodically	period	N	O
monitor	JJ	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
clinically	RB	clinically	clinically	clinic	N	O
for	IN	for	for	for	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
arrhythmic	JJ	arrhythmic	arrhythmic	arrhythm	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
palpitations	NNS	palpitations	palpitation	palpit	Y	O
,	,	,	,	,	N	O
lightheadedness	NN	lightheadedness	lightheadedness	lightheaded	Y	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
new	JJ	new	new	new	N	O
onset	JJ	onset	onset	onset	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
an	DT	an	an	an	N	O
ECG	NNP	ecg	ecg	ecg	Y	O
performed	VBD	performed	performed	perform	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
persists	NNS	persists	persists	persist	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
dose	JJ	dose	dose	dose	N	O
modification	NN	modification	modification	modif	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Second	JJ	second	second	second	N	O
Primary	NNP	primary	primary	primari	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	O

Other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
to	TO	to	to	to	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
including	VBG	including	including	includ	N	O
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
carcinomas	NN	carcinomas	carcinoma	carcinoma	N	I-AdverseReaction
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
second	JJ	second	second	second	N	B-AdverseReaction
primary	JJ	primary	primary	primari	N	I-AdverseReaction
malignancy	NN	malignancy	malignancy	malign	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
melanoma	NN	melanoma	melanoma	melanoma	Y	I-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
to	TO	to	to	to	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Tumor	NNP	tumor	tumor	tumor	N	O
Lysis	NNP	lysis	lysis	lysi	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
and	CC	and	and	and	N	O
take	VB	take	take	take	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
precautions	NNS	precautions	precaution	precaut	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
tumor	NN	tumor	tumor	tumor	N	O
lysis	NN	lysis	lysis	lysi	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

high	JJ	high	high	high	N	O
tumor	NN	tumor	tumor	tumor	N	O
burden	NN	burden	burden	burden	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Embryo	NNP	embryo	embryo	embryo	N	O
-	:	-	-	-	N	O
Fetal	JJ	fetal	fetal	fetal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
findings	NNS	findings	finding	find	N	O
in	IN	in	in	in	N	O
animals	NNS	animals	animal	anim	N	B-Animal
,	,	,	,	,	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
can	MD	can	can	can	N	O
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Ibrutinib	NNP	ibrutinib	ibrutinib	ibrutinib	N	O
caused	VBD	caused	caused	caus	N	O
malformations	NNS	malformations	malformation	malform	N	B-AdverseReaction
in	IN	in	in	in	N	O
rats	NNS	rats	rat	rat	N	B-Animal
at	IN	at	at	at	N	O
exposures	NNS	exposures	exposure	exposur	N	O
14	CD	14	14	14	N	O
times	NNS	times	time	time	N	O
those	DT	those	those	those	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MCL	NNP	mcl	mcl	mcl	N	O
and	CC	and	and	and	N	O
20	CD	20	20	20	N	O
times	NNS	times	time	time	N	O
those	DT	those	those	those	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CLL	NNP	cll	cll	cll	Y	O
or	CC	or	or	or	N	O
WM	NNP	wm	wm	wm	N	O
,	,	,	,	,	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
ibrutinib	NN	ibrutinib	ibrutinib	ibrutinib	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
560	CD	560	560	560	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
and	CC	and	and	and	N	O
420	CD	420	420	420	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Reduced	VBN	reduced	reduced	reduc	N	B-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
weights	NNS	weights	weight	weight	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
at	IN	at	at	at	N	O
lower	JJR	lower	lower	lower	N	O
exposures	NNS	exposures	exposure	exposur	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
women	NNS	women	woman	women	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
IMBRUVICA	NNP	imbruvica	imbruvica	imbruvica	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

